A partnership between Optum and genomic sequencing technology company Illumina is aiming to improve the safety and efficiency of human genome-based tests for disease detection and treatment, according to a Jan. 12 news release.
The partnership relies on Optum's new Evidence Engine, which aims to optimize, standardize and increase the adoption of precision medicine.
The Optum Evidence Engine will work alongside Illumina to conduct data analysis, research and craft best practices for personalized genomic-based testing, according to the news release.
"Through the Optum Evidence Engine, we are unlocking the power of personalized, precision health care to help advance disease detection and treatment for patients, and improve the overall health of communities we serve," said Optum Genomics CMO Jill Hagenkord, MD. "Our collaboration with Illumina aligns with Optum's aim to help people access the right medicine, at the right time, in the right setting, at the right cost, resulting in better health outcomes."
Initial uses for genomic-based testing include cancer treatment, genetic disease risk and drug metabolism.
For more information on the Optum Evidence Engine, click here.